OA13.03 Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, Double-Blind Phase 2 TrialY. Cheng,Q. Wang,Kai Li,Jianhua Shi,Lin Wu, B. Han,G. Chen,Jiaxi He, Wang J, H. Qin,Xia LiJOURNAL OF THORACIC ONCOLOGY(2018)引用 70|浏览40暂无评分关键词Anlotinib,3rd line,relapsed SCLCAI 理解论文溯源树样例生成溯源树,研究论文发展脉络